Cisplatin has 32 known drug interactions based on U.S. FDA drug labeling data. 21 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Altretamine, Bleomycin, Bleomycin Sulfate. Patients taking Cisplatin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 32
- Major
- 21
- Moderate
- 9
- Minor
- 2
Major (21)
- Cisplatin + Altretamine— Response duration was adversely affected when pyridoxine was used in combination with altretamine and cisplatin in advan…
- Cisplatin + Bleomycin— Nephrotoxic cisplatin decreases bleomycin renal clearance and increases half-life. Fatal bleomycin pulmonary toxicity re…
- Cisplatin + Bleomycin Sulfate— Nephrotoxic cisplatin decreases bleomycin renal clearance and increases half-life. Fatal pulmonary toxicity reported in …
- Cisplatin + Cytotoxic Agents— Concomitant use of ototoxic drugs with cisplatin increases risk of hearing loss and ototoxicity.
- Cisplatin + Furosemide— Risk of ototoxic and nephrotoxic effects when cisplatin and furosemide are given concomitantly.
- Cisplatin + Furosemide Injection 80 Mg/ 10 Ml— Risk of ototoxic and nephrotoxic effects if cisplatin and furosemide are given concomitantly. Administer furosemide at l…
- Cisplatin + Furosemide, Benzalkonium Chloride— Risk of ototoxic effects if cisplatin and furosemide are given concomitantly. Nephrotoxicity may be enhanced if furosemi…
- Cisplatin + Gentamicin Sulfate— Concurrent and/or sequential use should be avoided due to potential neurotoxicity and nephrotoxicity.
- Cisplatin + Melphalan Hydrochloride— Cisplatin may affect melphalan kinetics by inducing renal dysfunction and altering melphalan clearance.
- Cisplatin + Methotrexate— Caution must be exercised if high-dose methotrexate is administered in combination with cisplatin due to potential nephr…
- Cisplatin + Paclitaxel— Myelosuppression more profound when paclitaxel given after cisplatin; paclitaxel clearance decreased approximately 33% w…
- Cisplatin + Pentamidine Isethionate— Concomitant or sequential use may have additive nephrotoxic effects; should be closely monitored and avoided if possible…
- Cisplatin + Pyridoxine— Response duration was adversely affected when pyridoxine was used in combination with altretamine and cisplatin in advan…
- Cisplatin + Rituximab— Renal toxicity reported when rituximab used in combination with cisplatin.
- Cisplatin + Rituximab And Hyaluronidase— Renal toxicity when used in combination with cisplatin.
- Cisplatin + Rituximab-Abbs— Renal toxicity reported when rituximab is used in combination with cisplatin.
- Cisplatin + Rituximab-Arrx— Renal toxicity reported when rituximab used in combination with cisplatin.
- Cisplatin + Rituximab-Pvvr— Renal toxicity when used in combination with cisplatin
- Cisplatin + Topotecan— Combination causes severe myelosuppression with sequence-dependent interaction. At 1.25 mg/m² topotecan with 50 mg/m² ci…
- Cisplatin + Trilaciclib— COSELA may increase cisplatin exposure and kidney accumulation, causing dose-related nephrotoxicity. Close monitoring re…
- Cisplatin + Vancomycin Hydrochloride— Potentially nephrotoxic and neurotoxic drug requiring renal function monitoring when used concurrently with vancomycin.
Moderate (9)
- Cisplatin + Acidifying Agents— Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy, potentially reducing anticonv…
- Cisplatin + Carbamazepine— CYP3A4 inducer that decreases carbamazepine plasma levels. Carbamazepine levels and/or dosage adjustment may be necessar…
- Cisplatin + Fosphenytoin Sodium— May decrease phenytoin serum levels; dose adjustment may be required.
- Cisplatin + Gadobenate Dimeglumine— MultiHance may compete for MOAT transporter and prolong systemic exposure of cisplatin.
- Cisplatin + Magnesium Sulfate Heptahydrate— Cisplatin induces renal losses of magnesium.
- Cisplatin + Magnesium Sulfate In Dextrose— Cisplatin induces renal losses of magnesium, potentially leading to hypomagnesemia.
- Cisplatin + Phenytoin— May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
- Cisplatin + Phenytoin Sodium— May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
- Cisplatin + Thalidomide— Cisplatin causes peripheral neuropathy and concomitant use with thalidomide can cause additive effect; should be used wi…
Minor (2)
- Cisplatin + Ondansetron— Cisplatin does not affect the pharmacokinetics of ondansetron.
- Cisplatin + Ondansetron Hydrochloride— No effect on ondansetron pharmacokinetics observed in humans.